AI-Enhanced ECG for Cardiac Amyloidosis

Palo Alto (17 mi)

Overseen byAngela Dispenzieri, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: N/A

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to assess a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of cardiac amyloidosis (CA).

Eligibility Criteria

This trial is for Mayo Clinic providers who agree to participate and are involved in caring for adult patients within cardiology or hematology departments. There are no specific exclusion criteria, making it broadly accessible to these healthcare professionals.

Treatment Details

The study is evaluating an innovative AI-powered tool that analyzes ECG readings to help detect cardiac amyloidosis more effectively. This could potentially improve diagnosis rates of this heart condition.

2Treatment groups

Experimental Treatment

Active Control

Group I: Notification of the AI ECG algorithm and the A3E scoresExperimental Treatment1 Intervention

Provider-facing recommendation report that alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders

Group II: Usual CareActive Control1 Intervention

No alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders